Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:6/1/2010

es of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN at a dose of 3x10(10) TCID(50). Patients may continue to receive the trial combination therapy for up to eight, 21-day cycles and, thereafter, blinded placebo or blinded REOLYSIN until the patient has progressive disease or meets other criteria for removal from the trial. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium.

The primary endpoint for the trial is overall survival (OS); secondary endpoints include progression free survival (PFS), objective response rate (complete response (CR) + partial response (PR)) and duration of response, and safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin. The first stage of the trial is designed to enroll 80 patients. The second stage is adaptive, and is designed to enroll between 100 and 400 patients with the most probable statistical enrolment being 195 patients in this stage. This adaptive trial design allows frequent data evaluation to determine if the probability of reaching a statistically significant endpoint has been achieved.

The decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the Company's U.K. Phase 1 and Phase 2 combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Updated results from the U.K. Phase 1/2 trial reported in November 2009 demonstrated an overall response rate (PR and CR) of 42% and a total clinical benefit rate (PR + CR + stable disease) of 74%. The Company is currently conducting a confirmatory Phase 2 trial in the U.S. in patients with advanced head and n
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
4. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
5. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
6. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
7. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
8. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
9. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... SEATTLE , Aug. 1, 2014 /PRNewswire/ ... announce the launch of "Data InPress" ( ... tools for integrating multidimensional image data into ... DataViewer application and Video Injection Service. ... Photo - http://photos.prnewswire.com/prnh/20140731/132409 ...
(Date:7/31/2014)... Nearly 20,000 medical professionals and healthcare leaders gathered for ... Expo in Chicago from July ... and technology that will advance medicine and get patients ... July 30, more than 19,500 attendees had registered for ... with more than 10,000 of these attendees coming for ...
(Date:7/31/2014)... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington ... in bricks-and-mortar fashion, a development with potential value ... as field-effect transistors and photovoltaic cells. , Their ... 3D Crystalline Solids and 2D Self-Assembled Crystals," has ... a journal of the Royal Society of Chemistry. ...
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 North Shore ... York City, partnered with GI Energy, one of the nation’s ... a $13 million upgrade of its 43-year-old CHP system. The ... and in an effort to extend the life of the ... generators and associated electrical and heat recovery equipment, while maintaining ...
Breaking Biology Technology:Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2
... Reportlinker.com announces that a new market research ... Cytogenetics - technologies,markets and companies ... Summary This report deals ... than the classical use mainly to describe ...
... Technologies Corporation (NASDAQ: LIFE ) today announced ... online open-access resource for Ion Torrent users and developers, ... The sudden jump in membership began after Ion Torrent ... the Ion Personal Genome Machine™ (PGM™), the world,s first ...
... Inc. (OTCBB: MDXG), an integrated developer, manufacturer and ... processed from human amniotic membrane, announced today that ... convertible notes and warrants has been fully subscribed. ... October 15, 2011, the Company received $5,000,000 in ...
Cached Biology Technology:Cytogenetics - Technologies, Markets and Companies 2Cytogenetics - Technologies, Markets and Companies 3Cytogenetics - Technologies, Markets and Companies 4Cytogenetics - Technologies, Markets and Companies 5Cytogenetics - Technologies, Markets and Companies 6Cytogenetics - Technologies, Markets and Companies 7Cytogenetics - Technologies, Markets and Companies 8Cytogenetics - Technologies, Markets and Companies 9Cytogenetics - Technologies, Markets and Companies 10Cytogenetics - Technologies, Markets and Companies 11Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software 2Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software 3Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software 4Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software 5MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3
(Date:7/31/2014)... people make a rational choice to be liberal or ... it a matter of genetics?, Two political scientists from ... University say that neither conscious decision-making nor parental upbringing ... lean right. , A growing body of evidence shows ... core of political differences, the researchers say in the ...
(Date:7/31/2014)... Rim Fire was in full fury, raging swiftly from ... the backcountry of Yosemite National Park in California,s Sierra ... the battle began to turn, enacting a case study ... to fuel large, severe fires. , "When the Rim ... fire had been used as a management tool, rather ...
(Date:7/31/2014)... Biometrics industry sees growth as ... companies turn towards digital currency: NXT-ID, Inc. (OTCBB: NXTD), ... (NASDAQ: AMZN ), Facebook Inc. (NASDAQ: ... ) and Microsoft Corporation (NASDAQ: MSFT) NXT-ID, Inc., ... m-commerce market, announces a video featuring its next generation ...
Breaking Biology News(10 mins):Scientists find growing consensus: Political attitudes derive from body and mind 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6
... of the bacterial pathogen Haemophilus influenzae was published ... large, complex, medically, and commercially significant organisms including ... techniques used to derive these genetic sequences are ... potential errors lurking within the publicly available published, ...
... offer great hope for the treatment of some devastating diseases, ... usable and healthy for transplantation in patients has been an ... way to keep large quantities of these cells alive, a ... cells for therapeutic use at lower cost. , These ...
... and the University of Toronto have designed a ... inhibits anthrax toxin in animal and laboratory experiments. ... could be applied in designing potent therapeutics for ... the researchers. , Anthrax toxin, secreted by the ...
Cached Biology News:Study suggests that publicly available genome data may contain small but significant errors 2UCI researchers discover key factor for survival of human embryonic stem cells 2Anthrax inhibitor counteracts toxin, may lead to new therapeutics 2Anthrax inhibitor counteracts toxin, may lead to new therapeutics 3
...
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Replacement Parts for Electrophoresis Apparatus...
Histone H2A Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Detects ~14 kDa Histone H2A. It does not cross-react with other Histones. Reacts with human/mouse/rat. Performs w...
Biology Products: